Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850030 | 1.00 | CA1 (0.32) | CA1CA2MEN1NPC1ALDH1A1 | |
| SCHEMBL15417405 | 0.89 | CA1 (0.33) | CA1CA2MEN1NPC1ALDH1A1 | |
| SCHEMBL12252736 | 0.85 | CA12 (0.31) | CA1CA2 | |
| SCHEMBL17630152 | 0.83 | TGFBR1 (0.35) | CA1CA2MEN1ALDH1A1KMT2A | |
| SCHEMBL27400923 | 0.80 | TSHR (0.41) | CA1CA2MEN1ALDH1A1KMT2A | |
| SCHEMBL8907753 | 0.80 | CTSK (0.31) | MEN1NPC1ALDH1A1CYP1A2RAB9A | |
| SCHEMBL24024096 | 0.79 | — | — | |
| SCHEMBL7802720 | 0.79 | HDAC7 (0.34) | CA1CA2ZDHHC7 | |
| SCHEMBL23813407 | 0.79 | — | — | |
| SCHEMBL12250669 | 0.79 | HDAC7 (0.34) | CA1CA2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493580-B2 | Multivalent glycopeptide constructs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-11-15 | — | — | US | disclosed |
| US-9464116-B2 | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140271817-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130095173-A1 | MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-04-18 | — | — | US | disclosed |
| US-7879335-B1 | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095173-A1 | MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, GOLGA2, FUT5 | CA1 787/4885CA2 2639/4885MEN1 1666/4885 |
| US-20140271817-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SIGLEC7, B3GAT3, FUT6 | CA1 451/4885CA2 1879/4885MEN1 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.